omalizumab

Also known as IGE025, Ig gamma-1 chain C region, IGE25, Olizumab, RG-3648, Rhumab-E25

Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.

Key facts

Drug.Verifiedfields: changed
Drug.verifiedrevid: 458283563
Drug.type: mab
Drug.image: Omalizumab.png
Drug.caption: Omalizumab structure: (A) murine complementarity-determining region and (B) IgG1κ human framework
Drug.mab_type: mab
Drug.source: zu/o
Drug.target: IgE Fc region
Drug.tradename: Xolair
Drug.MedlinePlus: a603031
Drug.DailyMedID: Omalizumab
Drug.pregnancy_AU: B1
Drug.routes_of_administration

~16 min read

Article

16 sections

Contents

Medical uses
Allergic asthma
Chronic spontaneous urticaria
Food allergy
Chemistry and formulations
Mechanism of action
IgE in allergic diseases
Roles in non-allergic diseases
Adverse effects
History
Society and culture
Legal status
Biosimilars
Economics
See also
References

Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes.